<DOC>
	<DOCNO>NCT00941616</DOCNO>
	<brief_summary>The aim study ass pharmacokinetics ( PK ) , efficacy , safety Biostate速 subject Von Willebrand Disease ( VWD ) . Pharmacokinetic Component : PK parameter determine subgroup subject . Subjects complete PK component subsequently continue efficacy component study , either continue previously establish prophylaxis regimen continue receive on-demand treatment occurrence non-surgical bleeding ( NSB ) event . Efficacy Component : Three treatment arm define efficacy component study . ( 1 ) Subjects currently treat set prophylaxis regimen VWF product time study entry enrol `` Prophylaxis '' arm . ( 2 ) Subjects treat set prophylaxis regimen time study entry require VWF product treatment NSB event enrol `` On-demand '' arm commence use Biostate treatment NSB event . ( 3 ) Subjects enrol `` On-demand '' arm possibility enter `` Cross-over Prophylaxis '' arm receive additional 12 month prophylactic treatment .</brief_summary>
	<brief_title>Study pd VWF/FVIII Concentrate , Biostate速 , Subjects With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Diagnosed VWD Desmopressin acetate ( DDAVP ) treatment ineffective contraindicate available Evidence vaccination hepatitis A B ( presence antibody hepatitis A B ) within 10 year prior first dose Biostate速 Written inform consent give Exclusion Criteria ( participation PK component ) : Actively bleed immediately prior initial PK period Have receive DDAVP VWF product 5 day prior first dose study product Have Type 2B , 2N 2M VWD Exclusion Criteria ( subject ) : Requiring VWF product plan surgical procedure enrolment Have receive aspirin nonsteroidal antiinflammatory drug within 7 day prior first dose study product Known history , suspect , VWF FVIII inhibitor Suffering acute chronic medical condition , VWD , may affect conduct study Known suspect hypersensitivity previous evidence severe side effect Biostate速 , VWF/FVIII concentrate , human albumin Impaired liver function screen Evidence history ( within previous 12 month ) abuse drug substance , licit illicit Participation clinical study use investigational compound 3 month precede first day study drug administration , plan enter study study period . Females pregnant , breastfeed positive pregnancy test screening</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Von Willebrand Disease</keyword>
</DOC>